

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

BOSTON SCIENTIFIC CORP  
Form 8-K  
March 09, 2004

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

-----

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 4, 2004

BOSTON SCIENTIFIC CORPORATION

-----  
(Exact name of registrant as specified in charter)

DELAWARE	1-11083	04-2695240
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission file number)	(IRS employer identification no.)

ONE BOSTON SCIENTIFIC PLACE, NATICK, MASSACHUSETTS 01760-1537

-----

(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: (508) 650-8000

=====

ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.

On March 4, 2004, Boston Scientific Corporation (the "Company") issued a press release announcing that it received approval from the United States Food and Drug Administration to market its TAXUS(TM) Express(2) (TM) paclitaxel-eluting coronary stent system in the United States. A copy of the release is attached to this report as exhibit 99.1.

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

99.1 Press Release issued by the Company dated March 4, 2004.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BOSTON SCIENTIFIC CORPORATION

Date: March 9, 2004

By: /s/ Lawrence J. Knopf

-----  
Lawrence J. Knopf  
Vice President and Assistant General Counsel